GO
| HSI1 | 23,919.50 | 0.00 | -- |
| HSCEI1 | 8,057.59 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
2026-11-04 16:44:13 HEMAY PHARMA-B (00054.HK) announced that, based on prevailing market conditions, it has decided to postpone the global offering and listing. The international underwriting agreement for the international offering will therefore not be entered into, and the Hong Kong underwriting agreement for the Hong Kong public offering will not become unconditional. Application monies will be refunded in full without interest. The company emphasized that it remains committed to completing the global offering and listing at an appropriate time. HEMAY PHARMA-B's share offer period closed at noon today (4th). The company had originally been expected to debut next Monday (9th). The IPO involved the offering of 55.21 million H shares, with the offer price ranging from HKD15.5 to HKD18.9 per share. The deal was expected to raise up to HKD1.04 billion. ~ AASTOCKS Financial News Website: www.aastocks.com | |